DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Emend (Aprepitant) - Summary



EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist.

Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)

EMEND, in combination with other antiemetic agents, is indicated for the:

  • prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
  • prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) [see Dosage and Administration].
Prevention of Postoperative Nausea and Vomiting (PONV)

EMEND is indicated for the prevention of postoperative nausea and vomiting [see Dosage and Administration].

Limitations of Use

EMEND has not been studied for the treatment of established nausea and vomiting.

Chronic continuous administration is not recommended [see Warnings and Precautions].

See all Emend indications & dosage >>


Media Articles Related to Emend (Aprepitant)

Nausea and Vomiting (Causes, Natural Remedies, Diet, Medication)
Source: MedicineNet Anaphylaxis Specialty [2017.07.19]
Title: Nausea and Vomiting (Causes, Natural Remedies, Diet, Medication)
Category: Diseases and Conditions
Created: 1/31/2005 12:00:00 AM
Last Editorial Review: 7/19/2017 12:00:00 AM

more news >>

Published Studies Related to Emend (Aprepitant)

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. [2015]
3 trial to examine the safety and efficacy of such treatment in children... INTERPRETATION: Addition of aprepitant to ondansetron with or without

Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. [2014]
(HEC) in Asian countries... CONCLUSIONS: The addition of aprepitant to standard antiemetic treatment regimens

Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies. [2013]
analyses from four previously published studies... CONCLUSION: We conclude that for both the under 65years and the age 65 and over

Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. [2013]
Uncontrolled delayed nausea and vomiting remains a problem after high-dose preparative regimens used for autologous and allogeneic hematopoietic stem cell transplants. Recently, aprepitant was approved for highly and moderately emetogenic chemotherapy, and, in particular, is effective for decreasing delayed emesis...

Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. [2013]
Pre-clinical studies suggest that the neurokinin-1 (NK1) receptor may modulate the response to opioids, with NK(1) inactivation leading to decreased opioid reinforcement, tolerance and withdrawal...

more studies >>

Clinical Trials Related to Emend (Aprepitant)

Re-examination Study of EMEND (Aprepitant) (MK-0869-184) [Completed]
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation. Its aim is to reconfirm the clinical usefulness of EMEMD (aprepitant) through collecting the safety information according to the Re-examination Regulation for New Drugs.

Efficacy of Aprepitant (Emend´┐Ż) in Children [Recruiting]
The purpose of this study is to find out whether or not adding aprepitant(Emend«) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.

Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy [Not yet recruiting]
This study evaluates the addition of fosaprepitant to currently available antiemtic treatments of carboplatin chemotherapy-induced nausea and vomiting in advanced non-small cell lung cancer patients. Half of the patients will receive fosaprepitant in their first chemotherapy cycle, and a placebo on their second chemotherapy cycle. The other half of the patients will begin their first chemotherapy cycle.

Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects [Recruiting]
This is an open-label, single arm, phase I study to determine the safety, PK characteristics and anti-inflammatory effects of the NK-R1 coadministered with ritonavir-containing antiretroviral therapy in individuals with well-controlled viral replication. Our hypothesis is that Aprepitant will be safe, well tolerated, and will have anti-inflammatory properties when administered concomitantly with the protease inhibitor ritonavir.

A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134) [Terminated]
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.

more trials >>

Reports of Suspected Emend (Aprepitant) Side Effects

Nausea (24)Dyspnoea (18)Encephalopathy (18)Drug Interaction (16)Renal Failure Acute (14)Vomiting (9)Convulsion (9)Dehydration (9)Neutropenia (9)Septic Shock (9)more >>

Page last updated: 2017-07-19

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017